Summary
The antihypertensive effect of a new vasodilator with betablocking properties (SK & F 92657) was investigated in 10 patients with mild to moderate essential hypertension. After a mean treatment period of 26,5 weeks (6,5–49 weeks) blood pressure was significantly reduced, from 168±22/106±6 mmHg to 144±19/94±12 mmHg (p<0.05 and 0.025). The mean dose was 410 mg (100–700 mg). Heart rate decreased slightly from 77±12 to 70±8 beats/min. Plasma renin activity and plasma aldosterone showed only minor changes. Nausea, heavy dreams, facial and hand flushing and mild depression were reported as side effects. In most patients the symptoms disappeared without reduction in the dose. In one patient anaemia developed after 7 weeks and treatment with prizidilol was stopped. A slight but statistically significant decrease in haemoglobin concentration of 1.1±0.6 g/dl was observed in 5 of the 10 patients (p<0.02). Thus, a mean dose of prizidilol of 410±242 mg/day had a mean blood pressure lowering effect of 24/12 mmHg. In 7 of the 10 patients (70%) diastolic blood pressure could be reduced to 95 mmHg or less. However, the observed haematological side-effects should be carefully monitored in further studies and may limit the clinical use of prizidilol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bell A, Boyce MJ, Burland WL, Underwood PD (1980) Assessment in man of SK & F 92657 a novel antihypertensive compound with vasodilator and β-adrenoceptor blocking activity. Br J Clin Pharmacol 9: 299–300
Boyce M (1979) Volunteer studies with SK & F 92657, a novel antihypertensive agent with vasodilator and β-adrenoceptor blocking activity. Abstract 308. 6th Scientific meeting of the International Society of Hypertension, Göteborg 1980
Clancy A, Steiner JA, Manghani K, James IM (1981) Cardiovascular effects of SK & F 92657, a new antihypertensive agent with β-adrenoceptor antagonist and vasodilator properties. Br J Clin Pharmacol 11: 428
Collier JW, Pitcher DW (1980) Effects of SK & F 92657 on the superficial hand veins and forearm arterioles of man. Br J Clin Pharmacol 10: 567–571
Edmonstone WM, Manghani KK, Bell AJ, McLeod M, Milton-Thompson GJ, Burland WL (1981) Cardiovascular effects in man of intravenous prizidilol hydrochloride (SK & F 92657) a new antihypertensive agent. Br J Clin Pharmacol 12: 567–572
Gottlieb TB, Katz FH, Chidsey CA (1972) Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation 45: 571–582
Haber E, Koerner T, Page LB, Klimen B, Purnode A (1969) Application of radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol 29: 1349–1355
Hopkins SJ (1980) Prizidilol. Drugs of the future 5: 554–556
Karlberg BE, Larsson R, Oehman KP (1981) Prizidilol (SK & F 92657) in primary hypertension. Clin Sci 61: 461s-464s
Koch-Weser J (1974) Vasodilator drugs in the treatment of hypertension. Arch Intern Med 133: 1017–1027
Koch-Weser J (1976) Drug therapy: Hydralazine. N Engl J Med 295: 320–323
Larsson R, Karlberg BE, Norlaner B, Wirsen A (1981) Prizidilol, an antihypertensive with pre-capillary vasodilator and beta-adrenoceptor blocking actions in primary hypertension. Clin Pharmacol Ther 29: 588–593
Leonetti G, Terzoli L, Sala C, Bianchini C, Zanchetti A (1980) Dose response curve and time course of the antihypertensive effect of SK & F 92657, a beta-blocking and vasodilating compound. Clin Sci 59: 461–463s
Michelakis AM, McAllister RG (1972) The effect of chronic adrenergic blockade on plasma renin activity. J Clin Endocrinol Metab 34: 386–394
Pitcher DW, Curry PVL, Trounce JR (1980) An assessment of beta-adrenoceptor blockade in man (SK & F 92657), a new drug with combined vasodilator and beta-adrenoceptor. Br J Clin Pharmacol 9: 300–301 p
McMahon FG (1978) Hydralazine. In: FG McMahon (ed) Management of essential hypertension. Futura Publishing, New York, p 209
Steiner JA, Clancy A, Manghani KK, James IM (1981) Comparison of SK & F 92657, a new antihypertensive agent with beta-adrenoceptor antagonist and vasodilator activity to propranolol and hydralazine in normal volunteers. Br J Clin Pharmacol 12: 573–578
Taylor EM, Eden RJ, Fielden R, Owen DAA (1981) Studies on the autonomic nervous system with SK & F 92657, a new antihypertensive agent causing direct arterial vasodilation and beta-adrenoceptor blockade. J Cardivasc Pharmacol 3: 355–368
Taylor EM, Cameron D, Eden RJ, Fielden R, Owen DAA (1981) Haemodynamic profile of a new antihypertensive agent (D,L-3-(2-)3-t-Butylamino-2-hydroxypropoxy)phenyl)-6-hydrazinopyridazine) (SK & F 92657). J Cardivasc Pharmacol 3: 337–354
Taylor EM, Roe AM, Slater RA (1979) SK & F 92657, a novel antihypertensive acting by pre-capillary vasodilation and beta-adrenoceptor blockade. Clin Sci 57: 433s-435s
Ueda H, Yogi S, Kaneka Y (1968) Hydralazine and plasma renin activity. Arch Intern Med 122: 387–391
Vetter W, Vetter H, Siegenthaler W (1973) Radioimmunoassay for aldosterone without chromatography. 2. Determination of plasma aldosterone. Acta Endocrinol (Kbn) 74: 558–567
Zacest R, Gilmore E, Koch-Weser J (1972) Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med 286: 617–622
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lüscher, T., Havelka, J., Greminger, P. et al. Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension. Eur J Clin Pharmacol 23, 411–415 (1982). https://doi.org/10.1007/BF00605990
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00605990